Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431034 | 1.00 | EPHX2 (0.51) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL18947254 | 1.00 | EPHX2 (0.51) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL18809737 | 0.98 | EPHX2 (0.50) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL18431022 | 0.98 | EPHX2 (0.50) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL19489059 | 0.98 | EPHX2 (0.50) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL18809970 | 0.98 | EPHX2 (0.50) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL19489363 | 0.98 | EPHX2 (0.50) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL19489191 | 0.98 | EPHX2 (0.52) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL18431033 | 0.98 | EPHX2 (0.52) | EPHX2ROCK2ROCK1PKN2CYP3A4 | |
| SCHEMBL21443032 | 0.98 | EPHX2 (0.52) | EPHX2ROCK2ROCK1PKN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | EPHX2 1977/4885ROCK2 173/4885ROCK1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.